Motoki Horii
Overview
Explore the profile of Motoki Horii including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
72
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Imazaki K, Oishi K, Horii M, Shimizu K, Maeda S, Komura K, et al.
J Dermatol
. 2024 Nov;
52(3):e248-e250.
PMID: 39506507
No abstract available.
2.
Wang C, Oishi K, Kobayashi T, Fujii K, Horii M, Fushida N, et al.
Int J Mol Sci
. 2024 Jun;
25(11).
PMID: 38892317
The bleomycin-induced scleroderma model is a well-established and dependable method for creating a mouse model of SSc (systemic sclerosis). In the field of skin connective tissue diseases, increasing evidence from...
3.
Fushida N, Horii M, Fujii K, Mizumaki K, Kitano T, Sawada K, et al.
J Dermatol
. 2024 Feb;
51(5):704-713.
PMID: 38421809
Anti-human upstream-binding factor (anti-hUBF) antibodies have been reported predominantly in patients with connective tissue diseases (CTDs); these have also been reported in patients without CTDs such as hepatocellular carcinoma. Because...
4.
Fushida N, Horii M, Oishi K, Matsushita T
J Dermatol
. 2023 Nov;
51(4):607-611.
PMID: 37929294
We investigated the effectiveness of anifrolumab in treating systemic lupus erythematosus (SLE). We treated seven patients with SLE (age range, 31-68 years; median age, 48 years); one male and six...
5.
Hamaguchi Y, Yoshimura Y, Horii M, Fushida N, Kitano T, Sawada K, et al.
J Dermatol
. 2023 Oct;
51(1):62-69.
PMID: 37864453
Interstitial lung disease (ILD) is recognized a prognostic factor and leading cause of death in patients with systemic sclerosis (SSc). The aim of the present study is to clarify factors...
6.
Kuzumi A, Norimatsu Y, Matsuda K, Ono C, Okumura T, Kogo E, et al.
Front Immunol
. 2023 Sep;
14:1255540.
PMID: 37701440
Comprehensive autoantibody evaluation is essential for the management of autoimmune disorders. However, conventional methods suffer from poor sensitivity, low throughput, or limited availability. Here, using a proteome-wide human cDNA library,...
7.
Matsushita T, Fushida N, Horii M, Mizumaki K
J Dermatol
. 2023 Jan;
50(7):e228-e229.
PMID: 36700524
No abstract available.
8.
Nakabori I, Hamaguchi Y, Sawada K, Horii M, Fushida N, Kitano T, et al.
J Dermatol Sci
. 2022 Dec;
108(2):87-97.
PMID: 36567222
Background: Psoriasis is a chronic, inflammatory cutaneous disease. FcγRIIB is a low-affinity receptor for the IgG Fc fragment that provides a negative feedback pathway to down-regulate B-cell antigen receptor signaling....
9.
Mugii N, Hamaguchi Y, Horii M, Fushida N, Ikeda T, Oishi K, et al.
Rheumatology (Oxford)
. 2022 Jul;
62(3):1326-1334.
PMID: 35866689
Objective: To assess the longitudinal changes in nailfold videocapillaroscopy (NVC) in patients expressing myositis-specific autoantibodies [anti-aminoacyl-tRNA synthetase (ARS), anti-transcriptional intermediary factor 1 (TIF1), and anti-melanoma differentiation-associated gene 5 (MDA5)]. Methods:...
10.
Horii M, Fushida N, Ikeda T, Oishi K, Hamaguchi Y, Ikawa Y, et al.
J Dermatol
. 2022 Jun;
49(10):1012-1019.
PMID: 35751840
Systemic sclerosis (SSc) is an autoimmune disease characterized by skin and lung fibrosis. Over 90% of patients with SSc are positive for autoantibodies. In addition, the serum levels of B-cell...